Regional Brain Loss in NMR as a biomarker of SCA3-type dominant ataxia

by Instituto de Investigación Marqués de Valdecilla

Researchers from the hereditary ataxias and paraplegias CSUR os the University Hospital Marques de Valdecilla and IDIVAL´s neurodegenerative diseases group led by Dr. Jon Infante, participate in a Eu...

Read more

CNIC scientists coordinate a European project to develop a biomarker for the early identification of the vascular component in Alzheimer disease

by Centro Nacional de Investigaciones Cardiovasculares - CNIC

​The BioClotAD project, coordinated by Centro Nacional de Investigaciones Cardiovasculares (CNIC) scientist Dr Marta Cortés Canteli, who is supported by Spain's Miguel Servet Program, has been sele...

Read more

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

by Minoryx Therapeutics

Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces that th...

Read more

Researchers design a new family of molecules with high affinity to join altered receptors in neurodegenerative diseases

by Universitat de Barcelona

An article published in the Journal of Medicinal Che​mistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with ne...

Read more

Life after (neuronal) death

by Achucarro Basque Center for Neuroscience

A study led by the researchers of our centre shows that microglia is a sensor of newborn neuron death and maintains the equilibrium between life and death

Read more

New therapeutic strategy to treat Alzheimer’s

by Universitat de Barcelona

Researchers from the Institute of Neurosciences of the University of Barcelona (UBNeuro) have identified a potential therapeutic strategy to treat Alzheimer’s, according to a study published in Jour...

Read more

Grupo Témporing supports IDIBELL's research on ELA

by IBEC - Institut de Bioenginyeria de Catalunya

IDIBELL and the Temporing Group Company, headquartered in Barcelona, have reached a sponsorship agreement to boost funding for research on amyotrophic lateral sclerosis (ALS). Temporing is one of the ...

Read more

'Blobs' inside cells could be key to neurodegenerative diseases

by Centre for Genomic Regulation

Liquid droplets of molecules inside cells – similar to the blobs that form when oil and vinegar are mixed – could be behind neurodegenerative conditions such as Parkinson’s and motor neurone dis...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

ORYZON reports results and corporate upd...

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage...

Photos Stream